Paladin Labs Inc. and Endo Ventures Limited, subsidiaries of Endo International plc (NASDAQ: ENDP), today announced Health Canada's approval of Envarsus PA™(tacrolimus prolonged-release tablets) for the prophylaxis of organ rejection in kidney or liver t